Companiesandmarkets.com

Crohn's disease market to reach 1,481,386 cases by 2022

Press Release   •   Feb 26, 2013 12:30 GMT

The Crohn's disease market has been estimated to see the number of recorded cases increase from 1,337,272 in 2012 to 1,481,386 cases by 2022, experiencing an annual growth rate (AGR) of 1.08%.

Crohn's disease is a form of inflammatory bowel disease (IBD) characterised by recurrent inflammation of all or part of the gastrointestinal tract (CDC, 2011).

Globally, the incidence rates for Crohn's disease vary between 0.3 cases and 16.5 cases per 100,000 population, possibly indicative of an environmental influence in disease etiology (Economou et al., 2009).

From 2010 to 2020, the Crohn's disease drug market will experience modest annual growth of approximately 3% in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

However, this moderate growth rate will mask dramatic changes as sales of newer and emerging biological agents will outpace the decline in sales of older, established agents, which will face increasing generic erosion and declining use.

Two tumour necrosis factor-alpha (TNF-alpha) inhibitors, Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira, dominated the market in 2010, capturing more than three-quarters of market share.

Sales of Remicade and Humira are forecasted to peak at $3.3 billion in 2015, owing to increasing physician familiarity with these agents and continuing emergence of favourable post marketing clinical trial data. However, sales will be tempered starting in 2016 following the entry of bio similar TNF-alpha inhibitors to the Crohn's disease market.

Several therapies with different mechanisms of action are expected to launch for Crohn's disease beginning in 2014, including Millennium Pharmaceuticals' CAM inhibitor vedolizumab, Janssen Biotech/Janssen Cilag's interleukin (IL)-12/IL-23 inhibitor Stelara and GlaxoSmithKline/ChemoCentryx's chemokine receptor antagonist GSK-1605786 (formerly Traficet-EN or CCX-282B).

These agents hold the potential to viably fulfil some of the unmet need for effective and safe therapies for the TNF-alpha-refractory CD patient population. However, none of these agents will likely rival the efficacy or market share of the TNF-alpha inhibitors.

For more information on the Crohn's disease market, see the latest research: Chron's Disease Market

Follow us on Twitter @CandMResearch


Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.